Literature DB >> 29642828

[Comparison of Clinical Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution methods for determining the susceptibilities of Candida isolates].

Burcu Dalyan Cilo1, Tuncay Topaç1, Harun Ağca1, Sezcan Sağlam1, Kadir Efe1, Beyza Ener1.   

Abstract

Candida species are among the top 10 pathogens causing bloodstream infections associated with high morbidity, mortality. In spite of the development of new antifungal drugs, epidemiological studies have shown that resistance to antifungal drugs among Candida isolates is becoming a serious problem. The aim of this study was to compare the antifungal broth microdilution methods of the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) for amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole and anidulafungin susceptibility of Candida blood isolates. The study consisted of 74 Candida albicans, 67 Candida parapsilosis, 30 Candida glabrata, and 18 Candida tropicalis isolates. The minimum inhibitory concentrations were determined after 24 and 48 hour of incubation with CLSI method and only 24 hour of incubation with EUCAST method except anidulofungin. The MIC values obtained by both methods were considered to be compatible within ± 2 dilution limits. The categorical agreement between methods for each antifungal agent was assessed using clinical break points and epidemiological cut-off values. The agreement (± 2 dilution) between the methods was found to be species, drug, and incubation time dependent. After 24 hour incubation, good agreement category (> 90%) was detected between amphotericin B, itraconazole, posaconazole and anidulofungin, but was lower category (< 85%) was determined with fluconazole and voriconazole especially for relatively slow growing C.glabrata and C.parapsilosis isolates. Excellent categorical agreement (100%) was observed for amfoterisin B/C.parapsilosis, C.glabrata, C.tropicalis and anidulofungin/C.albicans, C.glabrata, C.tropicalis but least category was determined for posaconazole and C.albicans (71.6% at 24 hour; 73% at 48 hour). In vitro resistance of therapeutically used fluconazole and anidulafungin determined by both methods was rare among C.albicans (1.3%, 2.7% respectively), C.glabrata (0%, 3.3% respectively) and C.tropicalis (0%, 5.6% respectively) isolates but, an increase of non-susceptible isolates were observed among C.parapsilosis (11.9% at 24 hour of incubation; 17.9% at 48 hour of incubation) for fluconazole. There was also a cross resistance between fluconazole and voriconazole for three C.parapsilosis isolates and one multidrug resistant (fluconazole, itraconazole, posaconazole and anidulofungin) C.albicans isolate (fluconazole, itraconazole, posaconazole and anidulofungin). As a result in this study, it was determined thatboth methods were similar and can be used according to preference of laboratories. The CLSI antifungal susceptibility test results can be assessed at the end of 24 hour incubation, but sometimes it is important that the evaluation should be performed as a result of 48 hour incubation in slow growing species such as C.glabrata.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29642828     DOI: 10.5578/mb.63991

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  6 in total

1.  Broadened glycosylation patterning of heterologously produced erythromycin.

Authors:  Lei Fang; Guojian Zhang; Omar El-Halfawy; Max Simon; Eric D Brown; Blaine A Pfeifer
Journal:  Biotechnol Bioeng       Date:  2018-09-15       Impact factor: 4.530

2.  Optimization of Innovative Three-Dimensionally-Structured Hybrid Vesicles to Improve the Cutaneous Delivery of Clotrimazole for the Treatment of Topical Candidiasis.

Authors:  Maria Letizia Manca; Iris Usach; José Esteban Peris; Antonella Ibba; Germano Orrù; Donatella Valenti; Elvira Escribano-Ferrer; Juan Carmelo Gomez-Fernandez; Francisco José Aranda; Anna Maria Fadda; Maria Manconi
Journal:  Pharmaceutics       Date:  2019-06-06       Impact factor: 6.321

3.  A Comparative Study of the Microbiological Efficacy of Polymyxin B on Different Carbapenem-Resistant Gram-Negative Bacteria Infections.

Authors:  Qiong Lu; Hai-Hong Zhu; Guo-Hua Li; Ting-Ting Qi; Liang-Jun Ye; Xin-Qi Teng; Qiang Qu; Ge-Fei He; Jian Qu
Journal:  Front Med (Lausanne)       Date:  2021-02-09

4.  Comparison of Clinical Laboratory Standards Institute (CLSI) Microdilution Method and VITEK 2 Automated Antifungal Susceptibility System for the Determination of Antifungal Susceptibility of Candida Species.

Authors:  Burcu Dalyan Cilo; Beyza Ener
Journal:  Cureus       Date:  2021-12-06

5.  Clinical Efficacy of Polymyxin B in Patients Infected with Carbapenem-Resistant Organisms.

Authors:  Qiong Lu; Guo-Hua Li; Qiang Qu; Hai-Hong Zhu; Yue Luo; Han Yan; Hai-Yan Yuan; Jian Qu
Journal:  Infect Drug Resist       Date:  2021-05-28       Impact factor: 4.003

6.  Evaluation of the antibacterial effects and mechanism of Plantaricin 149 from Lactobacillus plantarum NRIC 149 on the peri-implantitis pathogens.

Authors:  Xiaolong Lin; Jiajia Xu; Zhiwei Shi; Yuedan Xu; Tao Fu; Ling Zhang; Fuming He
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.